<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Global economic growth on FinanClub</title>
    <link>https://finan.club/tags/global-economic-growth/</link>
    <description>Recent content in Global economic growth on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 13 Apr 2024 09:03:35 +0000</lastBuildDate><atom:link href="https://finan.club/tags/global-economic-growth/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Sat, 13 Apr 2024 09:03:35 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:26
Chances: FDA approval for AstraZeneca&amp;rsquo;s Fasenra for severe asthma in younger patients indicates potential for increased market share and revenue growth. AstraZeneca&amp;rsquo;s continued focus on research and development of new treatments is a positive sign for future innovation and expansion. AstraZeneca&amp;rsquo;s strong performance in the recent trading session indicates investor confidence and potential for further stock price growth.</description>
    </item>
    
  </channel>
</rss>
